Form 8-K

8-K — Sunshine Biopharma Inc.

Accession: 0001683168-26-005458

Filed: 2026-07-10

Period: 2026-07-08

CIK: 0001402328

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Financial Statements and Exhibits

Documents

8-K — sunshine_8k.htm (Primary)

EX-10.1 — RELEASE AGREEMENT (sunshine_ex1001.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: sunshine_8k.htm · Sequence: 1

8-K

false

0001402328

2026-07-08

0001402328

us-gaap:CommonStockMember

2026-07-08

0001402328

SBFM:CommonStockPurchaseWarrantsMember

2026-07-08

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM

8-K

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event

reported): July

8, 2026

SUNSHINE

BIOPHARMA INC.

(Exact name of registrant as specified in its charter)

Colorado

001-41282

20-5566275

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer ID No.)

333

Las Olas Way, CU4 Suite 433

Fort Lauderdale, FL 33301

(Address of principal executive offices) (Zip

Code)

(954) 330-6684

(Registrant’s telephone number, including area code)

Securities

registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

Common Stock, par value $0.001

SBFM

The Nasdaq

Stock Market LLC

Common Stock Purchase Warrants

SBFMW

The Nasdaq

Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities

Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange

Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under

the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under

the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive

Agreement.

On July 8, 2026, Sunshine Biopharma Inc. (the

“Company”) and the Company’s wholly-owned subsidiary, Nora Pharma Inc. (“Nora”) entered into an agreement

of transaction and mutual release (the “Release Agreement”) with Malek Chamoun, the former president of Nora. Pursuant to

the Release Agreement, the Company agreed to pay Mr. Chamoun CAD$1,500,000 (approximately US$1,058,565) in full and final settlement of

a dispute between the parties.

The foregoing description of the Release Agreement

is qualified by reference to the full text of the Release Agreement, which is filed as an exhibit to this report.

Item

9.01. Financial Statements and Exhibits.

Exhibit No.

Description

10.1

Release Agreement

104

Cover Page Interactive Data File (formatted in Inline XBRL).

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

Dated: July 10, 2026

SUNSHINE BIOPHARMA INC.

By: /s/ Dr. Steve N. Slilaty

Name: Dr. Steve N. Slilaty

Title: Chief Executive Officer

EX-10.1 — RELEASE AGREEMENT

EX-10.1

Filename: sunshine_ex1001.htm · Sequence: 2

Exhibit 10.1

AGREEMENT OF TRANSACTION AND MUTUAL RELEASE

Between:

Malek

Chamoun, domiciled at XXXXXXXXXX

(hereinafter “Chamoun”)

And:

Sunshine

Biopharma inc., having a place of business at 1565 Lionel-Boulet boulevard, Varennes, Québec, J3X 1P7

(hereinafter “Sunshine”)

And:

Nora

Pharma inc., having a place of business at 1565 Lionel-Boulet boulevard, Varennes, Québec, J3X 1P7

(hereinafter “Nora”)

(hereinafter collectively, “Sunshine”

and “Nora”, the “Corporations”)

(hereinafter collectively, the “Parties”)

WHEREAS Chamoun acted as President and

Chief Executive Officer of Nora from its incorporation in 2017 until October 20, 2022, at which time he sold the totality of his shares

in Nora to Sunshine pursuant to a Share Purchase Agreement dated October 20, 2022 (the “SPA”);

WHEREAS in connection with the transaction

contemplated by the SPA, Chamoun resigned as director, officer and employee and executed a new Employment Agreement dated October 20,

2022 (the “Employment Agreement”) and acted as President of Nora until his employment was terminated on April 10, 2025;

WHEREAS on May 22, 2026, Chamoun sent a

draft Originating Application (the “Application”) to the Corporations, claiming, notably, amounts allegedly owed under

the SPA in connection with the loss in value of shares of Sunshine received as partial consideration thereunder, indemnities in connection

with the termination of his employment, and moral and punitive damages for alleged harm to his reputation;

WHEREAS the Corporations dispute the allegations

set out in the Application and deny any liability whatsoever toward Chamoun, and have several claims against Chamoun arising from or related

to, directly or indirectly, his actions and conduct during his tenure as President of Nora, including, without limitation, in connection

with certain licensing and supply agreements, commissions paid, and transactions and arrangements involving related parties, as more fully

described in the letter from the Corporations’ attorneys to Chamoun’s attorneys dated June 19, 2026, the Excel spreadsheet

attached thereto and the updated version of this Excel spreadsheet sent to Chamoun’s attorneys on July 7, 2026 (collectively, the

“Cross-Claims”);

WHEREAS Chamoun disputes the Cross-Claims

and denies any liability whatsoever toward the Corporations;

WHEREAS the Parties, wishing to avoid the

delay, uncertainty, and expense of continued litigation, participated in a mediation held on July 8, 2026 (the “Mediation”)

before the Honourable Brian Riordan;

WHEREAS as a result of the Mediation, the

Parties have agreed to fully and finally settle, compromise, and release any and all claims and disputes between them, raised or that

could have been raised including, without limitation, those raised in the Application and the Cross-Claims (the “Dispute”),

on the terms and conditions set out in this Agreement;

NOW THEREFORE, in consideration of the

mutual covenants and agreements contained herein, the Parties agree as follows:

1. TERMS OF SETTLEMENT

1.1. In full and final settlement of the Dispute, and all matters referred to herein, the Corporations shall

pay to Chamoun the total amount of $1,500,000 CAD (the “Settlement Payment”), inclusive of all principal, interest,

and indemnity of any nature whatsoever.

1.2. The Settlement Payment shall be allocated as follows:

a) $479,208 as payment of the earn-out amount due under Section 2.6 of the SPA, which will be paid by Sunshine;

b) $752,782 as payment of the bonus for the period from January 1, 2024 to December 31, 2024, subject to

applicable statutory source deductions, which will be paid by Nora;

c) $219,561 as payment of the bonus for the period from January 1, 2025 to April 10, 2025, subject to applicable

statutory source deductions, which will be paid by Nora;

d) $25,634 as an indemnity in lieu of notice representing 2.25 months of Chamoun’s annual base salary

of $136,591 for 2025, subject to applicable statutory source deductions, which will be paid by Nora; and

e) $22,815 as reimbursement of expenses incurred by Chamoun prior to the termination of his employment which

will be paid by Nora.

1.3. Chamoun shall sell all common shares of Sunshine currently held by him (the "Shares")

within thirty (30) days of the execution of the Agreement and provide the Corporations with written evidence of the sale.

1.4. The Settlement Payment shall be paid by the Corporations to the trust account of Chamoun’s attorneys,

within ten (10) days following receipt of the written evidence that Chamoun sold all of his Shares.

1.5. Chamoun shall be solely responsible for any and all income taxes, source deductions, or other amounts

payable as a result of the receipt of the Settlement Payment, and shall indemnify and hold the Corporations harmless from any and all

tax claims, assessments, penalties, or interest raised by any taxing authority in connection therewith, other than in respect of source

deductions required to be withheld by Nora at the time of payment.

1.6. Each Party shall bear its own legal fees and disbursements incurred in connection with the Dispute, the

Mediation, and the negotiation of this Agreement.

2. NON-COMPETITION AND NON-SOLICITATION

2.1. The Parties acknowledge that Chamoun is, as of the date hereof, bound by certain non-competition and non-solicitation

covenants set out in the Employment Agreement and in a separate Non-Competition Agreement dated October 20, 2022 (the "Non-Compete

Agreement").

2.2. In consideration of the settlement set out herein, effective as of the execution of the Agreement, Chamoun

shall be fully and finally released and discharged from any and all non-competition and non-solicitation obligations set out in the Employment

Agreement and the Non-Compete Agreement, and such obligations shall be terminated and have no further force or effect without any other

formality or action notwithstanding what may be stipulated in the Employment Agreement and/or the Non-Compete Agreement.

2.3. For greater certainty, this Section 2 does not affect Chamoun's confidentiality obligations, if any, under

the Employment Agreement or the Non-Compete Agreement, which shall remain in full force and effect in accordance with their terms.

3. RELEASE BY CHAMOUN AS EMPLOYEE

3.1. As used in this Section 3, "Released Persons" means the Corporations, their predecessors,

successors, parent and related corporations, affiliates, divisions and their present, past or future directors, officers, shareholders,

managers, employees, representatives, trustees, beneficiaries, agents, contractors, insurers, and lawyers or legal representatives, financial

advisors, accountants, both current and former.

3.2. Chamoun, on behalf of himself and each of his executors, heirs, administrators, successors and assigns,

hereby irrevocably and unconditionally releases and discharges the Released Persons from any and all actions, causes of action, suits,

proceedings, executions, judgments, duties, debts, accounts, contracts and covenants (whether express or implied), claims and demands

whatsoever of any kind or type, for losses, liabilities, damages, indemnity, costs, expenses, interest or injury of every nature and kind,

including, without limiting the generality of the foregoing, relating to or arising out of his hiring or employment with Nora or any of

its affiliates or his termination of employment and benefits, including without limitation, any recourse, claim, demand, cause of action

or action, past, present or future, which Chamoun had, has, or may have under An Act Respecting Labour Standards, the Civil

Code of Québec, An Act Respecting Occupational Health and Safety, An Act Respecting Industrial Accidents and Occupational

Diseases, the Charter of Human Rights and Freedoms or any similar legislation or law, including without limitation, any claim

for indebtedness, wages, vacation pay, notice, compensatory indemnity in lieu of notice, moneys advanced, fees, expenses, participation

in profits or earnings, dividends, salary, bonuses, retirement or pension allowances, commissions, overtime, interests, moral or exemplary

damages or any other form of compensation.

4. MUTUAL RELEASE AND DISCHARGE

4.1. As used in this Section 4:

a) "Claims" means all actions, causes of action, suits, proceedings, executions, judgments,

duties, debts, accounts, contracts and covenants, claims and demands whatsoever of any kind or type, for losses, liabilities, damages,

indemnity, costs, expenses, interest or injury of every nature and kind, arising out of or in any way connected with the Dispute;

b) "Released Persons" means, as applicable, (i) in respect of the release granted by Chamoun,

the Corporations, their predecessors, successors, parent and related corporations, affiliates, divisions, and their present, past, or

future directors, officers, shareholders, managers, employees, representatives, trustees, agents, contractors, insurers, and lawyers or

legal representatives, financial advisors, and accountants, both current and former; and (ii) in respect of the release granted by the

Corporations, Chamoun and his heirs, executors, administrators, successors, representatives and assigns.

4.2. In consideration of the Settlement Payment and the mutual covenants set out herein, Chamoun, for himself

and his Released Persons, hereby irrevocably and unconditionally releases and discharges the Corporations and their Released Persons from

any and all Claims which Chamoun has now, or may have in the future, against any such Released Person.

4.3. In consideration of the mutual covenants set out herein, the Corporations for themselves and their Released

Persons, hereby irrevocably and unconditionally release and discharge Chamoun and his Released Persons from any and all Claims which the

Corporations have now, or may have in the future, against Chamoun and any such Released Person.

4.4. This release extends to all Claims of every nature and kind, known or unknown, suspected or unsuspected,

which now exist, and each Party expressly waives any rights it may have to assert Claims which it does not know or suspect to exist at

the time of executing this Agreement.

4.5. Each Party agrees and undertakes not to institute, maintain, or voluntarily assist any person or entity

in instituting or maintaining any action, proceeding, or complaint against the other Party or its Released Persons in connection with

any Claim released in accordance herewith.

4.6. Chamoun acknowledges that the Shares are publicly traded and that their value may fluctuate, and that

neither the Corporations nor any Released Person has made any representation or given any warranty as to their value. Chamoun hereby irrevocably

and unconditionally releases and discharges the Corporations and their Released Persons from any and all Claims relating to or arising

out of the value of the Shares and renounces any recourses against the Corporations and their Released Persons in relation to such Shares.

4.7. This release enures to the benefit of each of the Released Persons, and their respective successors, heirs,

liquidators, administrators, legal representatives and assigns, and is binding upon the Parties and their respective successors, heirs,

liquidators, administrators, legal representatives, and assigns.

5. TRANSACTION

5.1. The Parties acknowledge and agree that this Agreement constitutes a transaction within the meaning of

Article 2631 of the Civil Code of Québec.

5.2. The Parties acknowledge that they enter into this Agreement voluntarily, with full knowledge of its content

and legal effect, in order to prevent future litigation and to terminate the Dispute.

6. NO ADMISSION OF LIABILITY

6.1. This Agreement, the negotiations leading thereto, and the Settlement Payment are made solely for the purpose

of compromising disputed claims and avoiding the expense and inconvenience of litigation. Neither this Agreement nor anything contained

herein shall be construed as, or shall constitute, an admission of liability, wrongdoing, or fault on the part of any Party, all such

liability being expressly denied.

6.2. This Agreement and all communications, offers, and information exchanged between the Parties or their

counsel in connection with the Mediation and the negotiation of this Agreement are without prejudice and subject to settlement privilege,

and shall not be used, referred to, produced, or admissible in any proceeding whatsoever, other than a proceeding to enforce the terms

of this Agreement.

7. CONFIDENTIALITY

7.1. The Parties agree that the terms, and content of this Agreement, as well as the Mediation and settlement

discussions, shall not be disclosed, published, or communicated, directly or indirectly, to any third party, except to each Party’s

legal counsel, accountants, financial or tax advisors, on a need-to-know basis, provided such persons agree to maintain the confidentiality

thereof and to the extent required by law, applicable securities regulation, stock exchange rule, or by order of a court or other competent

authority, in which case the disclosing Party shall, to the extent legally permissible, provide prior written notice to the other Parties.

8. NON-DISPARAGEMENT

8.1. Each Party agrees that it shall not, directly or indirectly, make, publish, or cause to be made or published,

any statement, whether oral or written, including on social media, that disparages, defames, or is otherwise damaging to the reputation,

business, or character of any other Party and, in the case of the Corporations, of their current and former directors, officers, employees,

shareholders and beneficial owners, subject to each Party’s right to testify truthfully in any legal proceeding or to respond to

any legal or regulatory obligation.

9. REPRESENTATIONS AND WARRANTIES

9.1. Each Party represents and warrants that it has full power, capacity, and authority to enter into this

Agreement and to perform its obligations hereunder, and that this Agreement has been duly authorized, executed, and delivered by it.

9.2. Each Party represents and warrants that it has not assigned, transferred, or purported to assign or transfer,

to any person, any claim released pursuant to this Agreement.

9.3. Each Party acknowledges that it has read this Agreement in its entirety, has had the opportunity to review

it with, and to obtain the advice of, independent legal counsel of its choosing, fully understands its terms and consequences, and is

entering into it voluntarily and without duress or undue influence.

9.4. Chamoun represents and warrants to the Corporations that he has returned to Nora all property belonging

to the Corporations, namely, all contracts, documents, records and confidential information. Chamoun further represents and warrants that

he has permanently deleted and destroyed all confidential information of the Corporations in his possession, custody, or control and that

he has not retained, and will not retain, any copies thereof in any form or on any medium, device, system, or storage platform whatsoever

10. GOVERNING LAW AND JURISDICTION

10.1. This Agreement shall be governed by, and construed in accordance with, the laws of the Province of Quebec

and the federal laws of Canada applicable therein, without regard to conflict of laws principles.

10.2. The Parties irrevocably attorn to the exclusive jurisdiction of the courts of the Province of Quebec,

District of Montreal, for the purposes of any action or proceeding arising out of or relating to this Agreement.

11. LANGUAGE

11.1. The Parties acknowledge having expressly requested that this Agreement and all related documents be drafted

in the English language. Les parties reconnaissent avoir expressément exigé que la présente convention et tous

les documents s’y rattachant soient rédigés en langue anglaise.

12. GENERAL PROVISIONS

12.1. Interpretation. The recitals set out above form an integral part of this Agreement. The division

of this Agreement into sections and the insertion of headings are for convenience of reference only and shall not affect the interpretation

of this Agreement.

12.2. Entire Agreement. This Agreement constitutes the entire agreement between the Parties with respect

to its subject matter and supersedes all prior negotiations, representations, understandings, and agreements, whether written or oral,

relating thereto.

12.3. Amendments. No amendment, modification, or waiver of any provision of this Agreement shall be binding

unless made in writing and signed by all Parties.

12.4. Severability. If any provision of this Agreement is held to be invalid, illegal, or unenforceable,

such provision shall be severed from the remainder of this Agreement, which shall continue in full force and effect.

12.5. Counterparts. This Agreement may be executed in counterparts, including by electronic or PDF signature,

each of which shall be deemed an original, and all of which together shall constitute one and the same instrument.

Signatures on next page

IN WITNESS WHEREOF, the Parties have executed

this Agreement:

Montreal,

this 8th day of July, 2026

(s)

Malek Chamoun

Montreal,

this 8th day of July, 2026

Sunshine Biopharma inc.

(s)

Steve Slilaty

By: Steve Slilaty

Montreal,

this 8th day of July, 2026

Nora Pharma inc.

(s)

Steve Slilaty

By: Steve Slilaty

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Jul. 08, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 08, 2026

Entity File Number

001-41282

Entity Registrant Name

SUNSHINE

BIOPHARMA INC.

Entity Central Index Key

0001402328

Entity Tax Identification Number

20-5566275

Entity Incorporation, State or Country Code

Entity Address, Address Line One

333

Las Olas Way

Entity Address, Address Line Two

CU4 Suite 433

Entity Address, City or Town

Fort Lauderdale

Entity Address, State or Province

Entity Address, Postal Zip Code

33301

City Area Code

(954)

Local Phone Number

330-6684

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Common Stock [Member]

Title of 12(b) Security

Common Stock, par value $0.001

Trading Symbol

SBFM

Security Exchange Name

NASDAQ

Common Stock Purchase Warrants [Member]

Title of 12(b) Security

Common Stock Purchase Warrants

Trading Symbol

SBFMW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=SBFM_CommonStockPurchaseWarrantsMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: